Tuesday, November 2, 2021

Shoreline Biosciences Finds $140M

San Diego-based Shoreline Biosciences, a developer of cell immunotherapies for treating solid tumors and hematologic malignancies, has raised $140M in a financing round, the company said today. The funding was led by Ally Bridge Group, and also included new investors Eventide Asset Management, BeiGene, Irving Investors, Kingdon, NS Investment, Piper Heartland Healthcare Capital, and Superstring, along with current investors Boxer Capital, BVF Partners, L.P., Commodore Capital, Cormorant Asset Management, Janus Henderson Investors, Kite, a Gilead Company, Stork Capital, Wedbush Healthcare Partners and an undisclosed leading global investment firm. The company said that Frank Yu, Founder, CEO and CIO of Ally Bridge Group, joined the company's board of directors as part of the funding. Shoreline said the funding will help accelerate growth of its pipeline of iPSC-based cell immunotherapies for the treatment of seriously ill patients and enables the buildout of smart manufacturing capabilities. More information »